CLINICAL TRIALS PROFILE FOR ROTAVIRUS VACCINE, LIVE, ORAL, PENTAVALENT
✉ Email this page to a colleague
All Clinical Trials for rotavirus vaccine, live, oral, pentavalent
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02542462 ↗ | Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study | Completed | Centers for Disease Control and Prevention | Phase 4 | 2015-11-01 | This is a prospective randomized clinical trial that aims to evaluate the potential effects of the first dose of rotavirus vaccines on gastrointestinal motility and anatomy and blood and stool cytokine responses. It will also assess the association between these outcomes and the pattern of the shedding of vaccine strain rotavirus in the stool. Infants will be randomized to one of four arms: monovalent rotavirus vaccine (Rotarix®, RV1) alone, RV1 with other recommended vaccines, pentavalent rotavirus vaccine (RotaTeq®, RV5) alone, or RV5 with other recommended vaccines. Data derived from the pilot study will be used to assess the feasibility of conducting a larger scale study. |
| NCT02542462 ↗ | Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study | Completed | Children's Hospital Medical Center, Cincinnati | Phase 4 | 2015-11-01 | This is a prospective randomized clinical trial that aims to evaluate the potential effects of the first dose of rotavirus vaccines on gastrointestinal motility and anatomy and blood and stool cytokine responses. It will also assess the association between these outcomes and the pattern of the shedding of vaccine strain rotavirus in the stool. Infants will be randomized to one of four arms: monovalent rotavirus vaccine (Rotarix®, RV1) alone, RV1 with other recommended vaccines, pentavalent rotavirus vaccine (RotaTeq®, RV5) alone, or RV5 with other recommended vaccines. Data derived from the pilot study will be used to assess the feasibility of conducting a larger scale study. |
| NCT05032391 ↗ | Reactogenicity, Safety and Immunological Efficacy of the Live, Pentavalent Rotavirus Vaccine in Childhood Immunization | Completed | Limited Liability Company Pharm Aid | Phase 3 | 2019-02-22 | The first multicenter prospective, randomized, double-blind, placebo-controlled clinical trial of the pentavalent live vaccine for RVI prevention was conducted in Russia among healthy infants aged 2 months at the time of the first vaccination. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for rotavirus vaccine, live, oral, pentavalent
Condition Name
Clinical Trial Locations for rotavirus vaccine, live, oral, pentavalent
Trials by Country
Clinical Trial Progress for rotavirus vaccine, live, oral, pentavalent
Clinical Trial Phase
Clinical Trial Sponsors for rotavirus vaccine, live, oral, pentavalent
Sponsor Name
| Sponsor Name for rotavirus vaccine, live, oral, pentavalent | |
| Sponsor | Trials |
| Centers for Disease Control and Prevention | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| Limited Liability Company Pharm Aid | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
